

Corneal Crosslinking for Treatment of Corneal Neovascularization

NCT04787471

Status	RECRUITING
Phase	Phase 2, Phase 3
Sponsor	Price Vision Group
Enrollment	62 participants

Key Eligibility Criteria

Inclusion (3)

- years of age or older
- With active inflammation or infection causing vascularization and possibly melting of the cornea, or vessels extending into the cornea causing lipid deposition, or vascularization that could significantly increase the risk of rejection of a current or planned corneal transplant, or vessels that continue to extend into the cornea despite topical treatment with corticosteroids.
- Signed written informed consent.

Exclusion (3)

- Known sensitivity to treatment medications
- Current condition that in the investigator's opinion could compromise safety or data integrity.
- Pregnancy (including plan to become pregnant) or lactation during the course of the study

Locations (1 total)

Price Vision Group, Indianapolis, Indiana, United States